Area Development
A provider of plasmid DNA manufacturing and development services for DNA vaccine and gene therapy research, VGXI started construction on a 5,000 square foot expansion of its manufacturing facility in The Woodlands, Texas.

According to company officials, once completed the project will increase the company’s footprint by 17% and its cGMP manufacturing space by over 70%.

The upcoming development will add two new flexible-use GMP production areas to serve clients with both large and small scale needs, and a range of products from DNA vaccines to plasmid raw material for GMP viral vector production.

“With three key approvals in 2017 for CAR-T and AAV therapies, the gene therapy industry is rapidly maturing,” said VGXI’s President & CEO, Young Park. “We are excited to support the needs of our growing client base with increased flexibility and capacity across all service levels from Pre-Clinical to Highly Documented (HD) and cGMP grade plasmid production.”

VGXI, a wholly-owned subsidiary CMO of South Korea-based GeneOne Life Science, Inc., was founded in 1997 and has been operating as a GMP plasmid contract manufacturing organization since 2004. Over the 15 year period, the company said it has continued to grow in response to an increasing demand for high quality DNA, with its most recent expansion completed in 2016.